Disclosure of trial results in registries

Introduction

Disclosure of trial results in registries refers to the legal, ethical, and regulatory requirement to record and publish the outcomes of clinical trials in publicly accessible databases. Clinical trial registries are designed to maintain transparency in biomedical research by providing information about trial objectives, methodology, participant recruitment, safety outcomes, and treatment effectiveness.

Clinical trials are essential for developing medicines, vaccines, biological products, and advanced medical technologies. However, the selective publication of successful results and concealment of unsuccessful findings can create serious problems for public health and scientific integrity. Researchers may rely on incomplete evidence, healthcare professionals may make inappropriate treatment decisions, and patients may be exposed to unnecessary risks.

Therefore, disclosure of trial results in registries ensures that clinical research remains accountable to participants, regulatory authorities, scientific institutions, and society. In India, the Clinical Trials Registry–India (CTRI), the New Drugs and Clinical Trials Rules, 2019, and the ethical guidelines issued by the Indian Council of Medical Research provide an important framework for clinical trial transparency.

Meaning and objectives of trial result disclosure

Trial result disclosure means entering relevant findings of completed or terminated clinical studies into recognised clinical trial registries.

The information generally includes:

Trial identification: Registration number, sponsor details, investigators, and research institutions.

Participant information: Number of participants enrolled, completed, or withdrawn.

Study methodology: Trial design, treatment groups, and outcome measurements.

Efficacy results: Findings concerning the effectiveness of the tested medicine or intervention.

Safety results: Adverse events and other relevant safety observations.

Statistical findings: Analysis of primary and secondary outcomes.

Final conclusions: Overall research findings, limitations, and relevant interpretations.

The main objective is to ensure that research outcomes are not concealed merely because they are commercially unfavourable or scientifically unsuccessful.

Legal framework governing trial result disclosure in India

1. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, establishes the statutory foundation for regulating drugs and related activities in India.

Clinical trials involving new drugs must comply with applicable regulatory requirements. The Act supports government supervision of drug development and the protection of public health.

2. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019, establish requirements relating to clinical trial permissions, ethics committees, informed consent, participant safety, and compensation.

These rules provide the regulatory framework within which clinical trials must be conducted and documented.

Sponsors and investigators must comply with applicable reporting and record-maintenance obligations.

3. Clinical Trials Registry–India (CTRI)

The Clinical Trials Registry–India, operated by the ICMR's National Institute of Medical Statistics, provides a publicly accessible platform for registering clinical trials.

Prospective registration helps establish transparency before participant recruitment begins.

The registry contains information concerning trial design, research objectives, investigators, sponsors, recruitment status, and outcome measures. Results disclosure improves the usefulness of these records by allowing the public to examine the findings of completed studies.

4. ICMR National Ethical Guidelines, 2017

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, promote transparency, scientific integrity, informed consent, and participant protection.

The guidelines support responsible communication of research findings and discourage practices that undermine the scientific validity of clinical research.

5. International standards

The World Health Organization's International Clinical Trials Registry Platform (ICTRP) promotes international harmonisation of clinical trial registration.

Similarly, the Declaration of Helsinki emphasises the importance of public registration of human research and making research results publicly available, including negative and inconclusive findings.

Importance of disclosing trial results in registries

1. Prevention of selective reporting

Some research sponsors may prefer publishing positive results while withholding unsuccessful findings. Registry disclosure reduces this risk and provides a more complete scientific record.

2. Protection of clinical trial participants

Participants contribute their time, personal information, and health-related experiences to scientific research. Public reporting of results supports accountability towards their contribution.

3. Improvement in scientific research

Researchers can examine earlier trial outcomes, identify limitations, and avoid unnecessary repetition of unsuccessful studies.

4. Strengthening public confidence

Transparent reporting allows patients, medical professionals, and regulatory authorities to evaluate the available scientific evidence.

5. Regulatory accountability

Public trial records help regulators and research institutions monitor trial progress and identify inconsistencies between registered objectives and reported findings.

Legal and ethical challenges

Trial result disclosure involves several important legal difficulties.

1. Delayed disclosure: Sponsors may delay reporting results because of commercial interests or administrative difficulties.

2. Incomplete reporting: Some registries may contain trial information without sufficiently detailed outcome data.

3. Commercial confidentiality: Biotechnology companies may seek to protect unpublished discoveries, manufacturing processes, and commercially valuable research information.

4. Patient privacy: Clinical trial results may contain sensitive medical and genetic information. Public reporting must protect participant identities.

5. Scientific manipulation: Changing primary outcome measures after a trial begins or selectively reporting favourable findings may distort the scientific record.

6. International enforcement: Trials conducted across multiple jurisdictions may face different reporting requirements and enforcement mechanisms.

Relevant case laws

Indian courts have not yet established a specific general judicial rule requiring every clinical trial result to be published in a registry. However, several decisions provide important principles relevant to transparency, participant protection, and research accountability.

1. Swasthya Adhikar Manch v. Union of India (2013)

The Supreme Court considered concerns regarding clinical trials conducted in India, including informed consent, participant safety, regulatory supervision, and compensation.

Legal significance: The proceedings highlighted the responsibility of regulatory authorities to monitor clinical research and protect participants. Transparent trial records and reporting mechanisms are important components of such accountability.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court examined the legal requirements of informed consent in medical treatment.

Legal significance: Clinical research must respect participant autonomy and ensure adequate disclosure of relevant information. Transparent reporting of trial outcomes complements the ethical obligation to protect research participants.

3. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 of the Constitution.

Legal significance: Trial registries must balance public access to scientific findings with the protection of individual medical information. Results should be presented in a manner that does not unnecessarily identify participants.

4. Common Cause v. Union of India (2018)

The Supreme Court examined individual autonomy and dignity in medical decision-making.

Legal significance: The judgment reinforces the importance of respecting individual autonomy in healthcare. Clinical trial transparency must not undermine the dignity and privacy of research participants.

5. S.P. Gupta v. Union of India (1981)

The Supreme Court discussed the importance of transparency and public access to government-held information.

Legal significance: Its principles are relevant to public accountability when government authorities maintain clinical trial and regulatory records. Disclosure remains subject to applicable statutory exemptions and confidentiality protections.

Measures for strengthening registry disclosure

A stronger trial results disclosure framework should incorporate the following measures:

Require timely updating of trial registration records.

Promote disclosure of positive, negative, and inconclusive results.

Establish consistent reporting standards for clinical trial outcomes.

Strengthen regulatory monitoring of sponsor compliance.

Encourage publication of trial findings in recognised registries.

Protect confidential patient information through appropriate anonymisation.

Introduce institutional audits to identify incomplete or misleading reporting.

Improve coordination between CDSCO, CTRI, research institutions, and ethics committees.

Internationally recognised reporting standards, including the CONSORT guidelines, can also improve the quality and completeness of clinical trial reporting.

Conclusion

Disclosure of trial results in registries is an essential mechanism for ensuring transparency, scientific accountability, and public trust in clinical research. It prevents selective reporting, supports evidence-based healthcare, and recognises the contribution of clinical trial participants.

In India, the New Drugs and Clinical Trials Rules, 2019, the Drugs and Cosmetics Act, 1940, ICMR ethical guidelines, and Clinical Trials Registry–India provide an important regulatory foundation. Judicial decisions such as Swasthya Adhikar Manch v. Union of India, Samira Kohli v. Dr. Prabha Manchanda, and Justice K.S. Puttaswamy v. Union of India reinforce the importance of participant protection, informed consent, and privacy. Ultimately, an effective registry disclosure system must ensure that clinical trial findings are reported accurately and responsibly, regardless of whether the results are positive, negative, or inconclusive.